UHR PET/CT scan of the brain with… for Parkinson's (NCT07509125)
Distinguish Parkinson from related disorders
- Trial ID
- NCT07509125
- Official Title
- Ultra-High Resolution PET of the Human Brain and Spinal Cord in Healthy Aging, Dementia, Movement Disorders, ALS and Psychotic Disorders
- Goal
- Distinguish Parkinson from related disorders
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Study Type
- INTERVENTIONAL
- Enrollment
- 300 participants
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD), PSP - Progressive Supranuclear Palsy, MSA - Multiple System Atrophy, Dementia With Lewy Bodies (DLB), ALS With Frontotemporal Dementia (ALS/FTD), Adult Onset Psychotic Disorder, Very Late Onset Psychotic Disorder
- Interventions
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1, UHR PET/CT scan of the brain with ¹⁸F-MK6240, 3T MRI imaging of the brain
Summary For Families
Researchers are using ultra-high-resolution positron emission tomography (PET) to map how very small brain and spinal cord regions change with healthy aging and in conditions like Alzheimer’s, Parkinson’s and related movement disorders, ALS, and psychotic disorders, with the goal of spotting early changes that could improve diagnosis and guide future care. Participants will have scans on a new NeuroExplorer PET/computed tomography scanner and magnetic resonance imaging (MRI), using different tracers that show how the brain uses energy, how many connections exist between brain cells, markers of the brain’s dopamine system involved in movement, and buildup of a protein linked to Alzheimer’s, plus memory, mood, and movement or psychiatric assessments. The study enrolls healthy adults aged 18 to 90 and people with mild cognitive impairment from Alzheimer’s, ALS, clinically established Parkinson’s and related disorders (Parkinson’s patients must have a clinical diagnosis, an abnormal dopamine-transporter PET scan, and no significant cognitive impairment at baseline), REM sleep behavior disorder, or psychotic disorders.
Locations
- UZ Leuven, Leuven, Vlaams-Brabant, Belgium
Frequently Asked Questions
- What is this trial testing?
- This trial is studying UHR PET/CT scan of the brain with ¹⁸F-FDG. Researchers are using ultra-high-resolution positron emission tomography (PET) to map how very small brain and spinal cord regions change with healthy aging and in conditions like Alzheimer’s, Parkinson’s and related movement disorders, ALS, and psychotic disorders, with the goal of spotting early changes that could improve diagnosis and guide future care. Participants will have scans on a new NeuroExplorer PET/computed tomography scanner and magnetic resonance imaging (MRI), using different tracers that show how the brain uses energy, how many connections exist between brain cells, markers of the brain’s dopamine system involved in movement, and buildup of a protein linked to Alzheimer’s, plus memory, mood, and movement or psychiatric assessments. The study enrolls healthy adults aged 18 to 90 and people with mild cognitive impairment from Alzheimer’s, ALS, clinically established Parkinson’s and related disorders (Parkinson’s patients must have a clinical diagnosis, an abnormal dopamine-transporter PET scan, and no significant cognitive impairment at baseline), REM sleep behavior disorder, or psychotic disorders.
- Who can participate?
- Participants must be between 18 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 7 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: PET scan (minimally invasive); Blood draw (minimally invasive); MRI scan (non-invasive). Confirm the full schedule with the study coordinator.